公开(公告)号：US20250066733A1

公开(公告)日：2025-02-27

申请号：US18726179

申请日：2023-01-05

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： Arun SHARMA ,  Clive N. SVENDSEN

IPC: C12N5/077

Abstract: Described herein is a unique cell culture media that allows optimal growth of multiple cell types in the same system such as an organ-on-chip or organoid. Also described herein is use of the cell culture media in growing multiple cardiovascular cell types simultaneously in a single device or producing induced pluripotent stem cell (iPSC)-derived cardiac organoids containing iPSC derived-endothelial cells (iPSC-ECs) and iPSC derived-cardiomyocytes (iPSC-CMs). In some embodiments, a formulation for the cell culture media includes a base medium including glucose, a pH indicator, salts, amino acids, and vitamins; recombinant human albumin; L-ascorbic acid 2-phosphate; and at least one or more of insulin, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), a synthetic analogue of insulin-like growth factor (IGF)-I, heparin, or hydrocortisone.

公开(公告)号：US12222352B2

公开(公告)日：2025-02-11

申请号：US16476480

申请日：2018-01-29

Applicant: Cedars-Sinai Medical Center

Inventor： Mark Pimentel ,  Daniel Furst

IPC: G01N33/53 ,  G01N33/564

Abstract: Described herein are methods of diagnosing systemic sclerosis (SSc) involving the detection of anti-vinculin antibodies. Also described herein are methods of selecting treatment of subjects diagnosed with systemic sclerosis (SSc), and methods of treating systemic sclerosis (SSc).

公开(公告)号：US20250025487A1

公开(公告)日：2025-01-23

申请号：US18571924

申请日：2022-06-30

Applicant: Cedars-Sinai Medical Center

Inventor： Eduardo Marbán ,  Ahmed G. Ibrahim

IPC: A61K31/712 ,  A61P9/04 ,  A61P9/10 ,  A61P21/00 ,  C12N15/113

Abstract: An isolated nucleic acid that includes the nucleotide sequence: CGUCCGAUGGUAGUGGGUUAUCAG (SEQ ID NO: 12) is provided. In some embodiment, the nucleic acid includes at least one chemically-modified nucleotide. The nucleic acid and composition containing same find use in treating conditions associated with inflammation and/or fibrosis, for example, without limitation, heart conditions, such as hypertrophic myocardiopathy, myocardial infarction, and heart failure with preserved ejection fraction; muscle disorders, such as muscular dystrophy; skin disorders, such as scleroderma; and inflammatory conditions, such as autoimmune conditions or inflammatory conditions associated with a viral infection.

公开(公告)号：US20250000958A1

公开(公告)日：2025-01-02

申请号：US18764576

申请日：2024-07-05

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： Stanley Jordan ,  Jua Choi ,  Ashley A. Vo

IPC: A61K38/57 ,  A61K9/00

Abstract: Described herein are methods for improving kidney function in subjects that have undergone kidney transplant. An effective amount of one or more complement component 1 esterase inhibitors is administered to the subject, resulting in long-term improvement on kidney allograft function.

公开(公告)号：US20240426842A1

公开(公告)日：2024-12-26

申请号：US18640030

申请日：2024-04-19

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US20240392382A1

公开(公告)日：2024-11-28

申请号：US18672478

申请日：2024-05-23

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： Andrew Hendifar ,  Patrick Lee

IPC: C12Q1/6886 ,  A61K31/495 ,  A61K31/7064

Abstract: We describe a new genomic signature (MEN1 mut/DAXX wt) that correlates with PNET response to CAPTEM therapy. MEN1-mut/DAXX-wt status correlates with longer progression-free survival on CAPTEM in patients with pancreatic neuroendocrine tumors, relative to patients with MEN1-wt or DAXX-mut.

公开(公告)号：US12146137B2

公开(公告)日：2024-11-19

申请号：US16966840

申请日：2019-01-30

Applicant: Cedars-Sinai Medical Center

Inventor： Eduardo Marbán ,  Linda Cambier ,  Geoffrey De Couto

IPC: C12N15/113 ,  A61K35/34 ,  A61K47/69 ,  A61P9/00 ,  A61P13/12 ,  A61P37/02

Abstract: Some embodiments of the methods and compositions provided herein relate to treating a subject suffering from hypertension, a cardiac injury, or a metabolic disorder. Some embodiments include administering an exosome to a subject. Some embodiments include administering an oligonucleotide to the subject. In some embodiments, the oligonucleotide comprises a Y-RNA or Y-RNA fragment such as EV-YF1 or EV-YF1-U16. In some embodiments, the oligonucleotide or exosome also has a therapeutic effect on the subject.

公开(公告)号：US20240368263A1

公开(公告)日：2024-11-07

申请号：US18649944

申请日：2024-04-29

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Jeffry D. WATKINS ,  Cindy T. DICKERSON ,  J. Monty WATKINS ,  Patricia MCNEELEY ,  Janine Bilsborough ,  Bradley Henkle ,  Stephan R. Targan

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  C07K16/28 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63

Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

公开(公告)号：US20240358751A1

公开(公告)日：2024-10-31

申请号：US18681641

申请日：2022-08-19

Applicant: Cedars-Sinai Medical Center

Inventor： Vanessa Alexandra Moser ,  Clive Niels Svendsen ,  Helen Goodridge ,  Alexander LaPerle

IPC: A61K35/15 ,  A61P25/28 ,  C12N5/0786

CPC classification number: A61K35/15 ,  A61P25/28 ,  C12N5/0645 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2334 ,  C12N2501/26 ,  C12N2501/845 ,  C12N2506/45

Abstract: Mononuclear phagocytes derived from induced pluripotent stem cells, denoted as iMPs, which comprise monocytes generated from the induced pluripotent stem cells and optionally further macrophages generated from the induced pluripotent stem cells, are provided for use in improving cognitive function, improving neural health, and/or alleviating or treating a neurodegenerative disorder in a mammal In various embodiments, the iMPs produce macrophages after transplantation or after being stimulated in vitro, and/or express macrophage markers. We showed that iMPs upon administration improve cognition and neural healthy in rodent models of aging, Alzheimer's disease, and amyotrophic lateral sclerosis. Treatment methods are also provided using mononuclear phagocytes generated from autologous stem cells or from induced pluripotent stem cells obtained from autologous cells in patients in need of treatment or prophylaxis of a neurodegenerative disorder.

公开(公告)号：US20240336691A1

公开(公告)日：2024-10-10

申请号：US18546947

申请日：2022-02-17

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Allison LUO ,  Olivier LAURENT ,  Ernesto J. MUNOZ ,  Janine BILSBOROUGH ,  Bradley HENKLE ,  Stephan R. TARGAN ,  Dermot P. MCGOVERN

IPC: C07K16/28 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P11/00

CPC classification number: C07K16/2875 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61P11/00 ,  C07K2317/21

Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of diseases and/or conditions in the lung.